Mouse anti Human CD5 FITC - CD19 PECatalog number: 0519S
|Isotype||IgG2a (F)/IgG1 (PE)|
Bi-Testª Reagents (FITC/RPE)
Identification of CD5 human T cells expressing the 67,000 M.W. surface antigen, 85% peripheral blood lymphocytes that form rosettes with sheep red blood cells (E+) and a small subset of B cells. Identification of CD19 PE human B cells associated approximately 10% of peripheral blood lymphocytes expressing the 95,000 M.W. surface antigen.
Synonyms: CD5 FITC - CD19 PE
Immunogen: CD5=Derived from the hybridization of mouse NS-1/Ag4 myeloma cells with spleen cells of BALB/c mice immunized with human t-acute lymphoblastic leukemia (ALL) cells.
Product Form: Bi-Test (FITC/RPE) Reagent
Formulation: Provided as solution in phosphate buffered saline with 0.08% sodium azide and 0.2% carrier protein
Purification Method: Protein A/G Chromatography
Concentration: Titered for flow cytometry
PBMC: Add 10 µl of MAB/10^6 PBMC in 100 µl PBS. Mix gently and incubate for 15 minutes at 2º to 8ºC. Wash twice with PBS and analyze or fix with 0.5% v/v of paraformaldehyde in PBS and analyze. WHOLE BLOOD: Add10 µl of MAB/100 µl of whole blood. Mix gently and incubate for 15 minutes at room temperature 20ºC. Lyse the whole blood. Wash once with PBS and analyze or fix with 0.5% v/v of paraformaldehyde in PBS and analyze. See instrument manufacturer’s instructions for Lysed Whole Blood and Immunofluorescence analysis with a flow cytometer or microscope.
Functional Analysis: Flow Cytometry Staining
Product should be stored at 4-8ºC. DO NOT FREEZE
Product Stability: See expiration date on vial
Shipping Conditions: Room Temperature
This product is intended FOR RESEARCH USE ONLY, and FOR TESTS IN VITRO, not for use in diagnostic or therapeutic procedures involving humans or animals. It may contain hazardous ingredients. Please refer to the Safety Data Sheets (SDS) for additional information and proper handling procedures. Dispose product remainders according to local regulations.This datasheet is as accurate as reasonably achievable, but Exalpha Biologicals accepts no liability for any inaccuracies or omissions in this information.
1. Anti-DNA Antibody Production by CD5+ and CD5- B Cells of Patients with Systemic Lupus Erythematosus. Suzuki,N., Sakane, T., Engleman, E.G.. J. Clin. Invest. 1990 Ja;85(1):238-47. 2. Characteristics of CD11c+ CD5+ Chronic B cell Leukemias and the Identification of Novel Peripheral Blood B cell Subsets with Chronic Lymphoid Leukemia Immunophenotypes. Wormsley ,S.B., Baird, S.M., Gadol, N., Rai K.R., Sobol,R.E.. Blood 1990 July. 76(1):123-30. 3. Stimulation of CD5 Enhances Signal Transduction by the T cell Antigen Receptor. Imboden, J.B., June, C.H., McCutcheon, M.A, Ledbetter ,J.A.. J. Clin. Invest. 1990 Ja; 85(1):130-4 4. Surface Immunoglobulin Ligands and Cytokines Differentially Affect Proliferation and Antibody Production by Human CD5+ and CD5- B Lymphocytes. Nawata, Y., Stall, A.M., Herzenberg, L.A., Eugui, E.M., Allison,A.C., Int. Immunol. 1990;2(7):603-14 5. Evidence for Differential Responsiveness of Human CD5+ and CD5- B cell Subsets to T Cell Independent Mitogens. Zupo, S., Dono, M., .Azzoni ,L., Chiorazzi, N., Ferrarini, M.. Eur. J. Immunol. 1991 Fe. 21(2):351-9 6. Functional Properties of CD19+ B Lymphocytes Positively Selected from Buffy Coats by Immunomagnetic Separation. Funderud, S., Erikstien, B., Asheim, H.C., Nustad ,K., Stokke, T., Blomhoff, H.K., Holte, H., Smeland, E.B.. Eur. J. Immunol. 1990 Ja;20(1):201-6 7. Thymic B Cells from Myasthenia Gravis Patients are Activated B Cells. Phenotypic and Functional Analysis. Leprince, C., Cohen-Kaminsky, S., Berrih-Aknin, S., Vernet-Der Garabedian, B., Treton, D., Galanaud, P., Richard, Y., J. Immunol. 1990 Oct., 145(7):211522. 8. Prognostic Significance of CD34 Expression in Childhood B Precursor Acute Lymphocytic Leukemia: A Pediatric Onocology Group Study. Borowitz, M.J., Shuster, J.J., Civin, C.I., Carrol, A.J., Look, A.T., Behm, F.G., Land, V.J., Pullen, D.J., Crist, W.M.. J. Clin. Onol. 1990 Au;8(8):1389-98. 9. Biphenotypic Acute Leukemia in Adults. Sulak, L.E., Clare, C.N., Morale, B.A., Hansen, K.L., Montiel, M.M.. Am. J. Clin. Path. 1990 Ju;94(1):54-8. 10. Intersection of the Complement and Immune Systems: A Signal Transduction Complex of the B Lymphocyte Containing Complement Receptor type 2 and CD19. Matsumoto, A.K., Kopicky-Burd , J., Carter, R.H., Tuveson, D.A., Tedder, T.F., Fearon, D.T., J. Exp. Med. 1991 Jan. 173(1):55-64.
Database Name: UniProt
Accession Number: P06127, P15391
Safety Datasheet(s) for this product:
Mouse anti Human CD5 FITC - CD19 PE
$219.00Add To Cart